Skip to main content

Featured

5 Things to Know Today: U.S. Alcohol Ban, GDP Day, 5.25% Yields (Sept 29)

  Tuesday September 29, 2026 A U.S. import ban on Canadian booze kicks in, Statistics Canada reports July GDP, and U.S. bond yields sit at levels not seen since 2007. Here are the five things that matter for your wallet today. 1 The U.S. ban on Canadian alcohol takes effect today As of 12:01 a.m. ET, the U.S. is refusing entry to many Canadian beer, wine, cider and spirits shipments, along with whey products, molasses and larger motorcycles. The measures were signed Sept. 8 and largely replace the 50% tariffs that applied to these goods. Bottles already in the U.S. can still be sold, and product shipped in bulk to be bottled south of the border appears to fall outside the ban. Canadian producers say pivoting to domestic sales won't be easy, because a patchwork of provincial rules complicates selling across borders. What it means for you: The ban hits exports, not what you pay at the store. The exposure is for people who work in or own shares of brewers, distillers and wineries, a...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment